Linda A Weffald - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Linda A Weffald

Showing results (1-10 of 10) with videos related to

Pageof 1

Sort By:

Pharmacotherapy|January 27, 2007

Myopathy associated with atorvastatin-ezetimibe combination therapyLinda A Weffald, Lynn A Flach

Drugs & Aging|January 18, 2019

Drugs Contributing to Anticholinergic Burden and Risk of Fall or Fall-Related Injury among Older Adults with Mild Cognitive Impairment, Dementia and Multiple Chronic Conditions: A Retrospective Cohort StudyAriel R Green, Liza M Reifler, Elizabeth A Bayliss, et al.

Drugs & Aging|February 7, 2018

Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic BurdenAriel R Green, Liza M Reifler, Cynthia M Boyd, et al.

Journal of the American Medical Directors Association|June 3, 2025

Central Nervous System Polypharmacy Among People Living With DementiaElizabeth A Bayliss, J David Powers, Linda A Weffald, et al.

Journal of General Internal Medicine|July 31, 2020

Designing a Primary Care-Based Deprescribing Intervention for Patients with Dementia and Multiple Chronic Conditions: a Qualitative StudyAriel R Green, Cynthia M Boyd, Kathy S Gleason, et al.

Journal of the American Geriatrics Society|December 12, 2022

Intervention design in cognitively impaired populations-Lessons learned from the OPTIMIZE deprescribing pragmatic trialOrla C Sheehan, Kathy S Gleason, Elizabeth A Bayliss, et al.

Patient Education and Counseling|October 22, 2025

Integrating patient education on deprescribing into care delivery: Learnings from the Optimize pragmatic trialElizabeth A Bayliss, Kathy S Gleason, Orla C Sheehan, et al.

Pharmacoepidemiology and Drug Safety|April 8, 2025

Discontinuation Categories Underlying Gaps in Dispensing for Six Medication GroupsElizabeth A Bayliss, Glenn K Goodrich, Jennifer C Barrow, et al.

JAMA Internal Medicine|March 28, 2022

Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians: The OPTIMIZE Pragmatic Cluster Randomized TrialElizabeth A Bayliss, Susan M Shetterly, Melanie L Drace, et al.

Drugs & Aging|November 20, 2023

Evaluating the Safety of an Educational Deprescribing Intervention: Lessons from the Optimize TrialCynthia M Boyd, Susan M Shetterly, John D Powers, et al.

Pageof 1

Search research articles

Showing results (1-10 of 10) with videos related to

Sort By:

Pageof 1

Pharmacotherapy|January 27, 2007

Myopathy associated with atorvastatin-ezetimibe combination therapyLinda A Weffald, Lynn A Flach

Drugs & Aging|January 18, 2019

Drugs Contributing to Anticholinergic Burden and Risk of Fall or Fall-Related Injury among Older Adults with Mild Cognitive Impairment, Dementia and Multiple Chronic Conditions: A Retrospective Cohort StudyAriel R Green, Liza M Reifler, Elizabeth A Bayliss, et al.

Drugs & Aging|February 7, 2018

Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic BurdenAriel R Green, Liza M Reifler, Cynthia M Boyd, et al.

Journal of the American Medical Directors Association|June 3, 2025

Central Nervous System Polypharmacy Among People Living With DementiaElizabeth A Bayliss, J David Powers, Linda A Weffald, et al.

Journal of General Internal Medicine|July 31, 2020

Designing a Primary Care-Based Deprescribing Intervention for Patients with Dementia and Multiple Chronic Conditions: a Qualitative StudyAriel R Green, Cynthia M Boyd, Kathy S Gleason, et al.

Journal of the American Geriatrics Society|December 12, 2022

Intervention design in cognitively impaired populations-Lessons learned from the OPTIMIZE deprescribing pragmatic trialOrla C Sheehan, Kathy S Gleason, Elizabeth A Bayliss, et al.

Patient Education and Counseling|October 22, 2025

Integrating patient education on deprescribing into care delivery: Learnings from the Optimize pragmatic trialElizabeth A Bayliss, Kathy S Gleason, Orla C Sheehan, et al.

Pharmacoepidemiology and Drug Safety|April 8, 2025

Discontinuation Categories Underlying Gaps in Dispensing for Six Medication GroupsElizabeth A Bayliss, Glenn K Goodrich, Jennifer C Barrow, et al.

JAMA Internal Medicine|March 28, 2022

Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians: The OPTIMIZE Pragmatic Cluster Randomized TrialElizabeth A Bayliss, Susan M Shetterly, Melanie L Drace, et al.

Drugs & Aging|November 20, 2023

Evaluating the Safety of an Educational Deprescribing Intervention: Lessons from the Optimize TrialCynthia M Boyd, Susan M Shetterly, John D Powers, et al.

Pageof 1